Approximately 50% of patients with neuroblastoma exhibit a high-risk phenotype (HRNB), characterized by metastases in patients >18 months of age or the presence of an amplified MYCN gene in patients of any age [2,3]. This evidence concerns the gene MYCN and neuroblastoma.